Mounjaro Week 3: What the Evidence Says and What You Might Notice

Why week 3 often feels like a plateau before the progress

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and tracked them over 72 weeks, ultimately finding average body-weight reductions of around 20–21% at the 15 mg dose. But those results accumulated gradually. The early weeks, particularly weeks 1 through 4 at 2.5 mg, were about tolerability rather than transformation. That framing matters: the starter dose is there to settle your digestive system into the medicine, not to deliver immediate scale movement.

What many people do notice by week 3 is a shift in appetite. Portions feel like enough sooner. The urge to snack between meals quietens. Some people describe eating half what they normally would and feeling genuinely full. These are early signs that tirzepatide's dual receptor action is taking hold, and they tend to precede measurable weight loss by a week or two, because the body is still calibrating. If you started Mounjaro recently, what to expect in week 1 gives useful context for the adjustment phase you have just come through.

It is also worth knowing that water retention and GI changes can temporarily mask early fat loss on the scales. A number that barely moves in week 3 does not mean nothing is happening. The timeline for how long Mounjaro takes to work covers this in more detail, including why clinical guidance positions the first four weeks as a settling-in period rather than a measure of the medicine's effectiveness.

Side effects that tend to be most noticeable around week 3

The GI side effects associated with tirzepatide (nausea, loose stools, indigestion, burping, and for some people constipation) are typically most prominent in the first two to three weeks. For many people, week 3 marks the tail end of that adjustment window, and symptoms begin to ease. For others, week 3 is still uncomfortable, particularly if the injection day triggers a day or two of queasiness.

A question our prescribers hear most weeks is whether nausea at week 3 means the treatment is not working or is not suitable. In most cases, nausea at this stage is a normal part of the body adjusting to slowed gastric emptying, not a signal to stop. Eating smaller meals, avoiding rich or fatty foods around injection day, and staying well hydrated all make a practical difference. The NHS tirzepatide patient information page covers these strategies alongside what to watch for.

Serious symptoms need prompt attention regardless of timing. Severe stomach pain that spreads to the back, with or without vomiting, should be assessed urgently, the MHRA specifically flagged acute pancreatitis as a known, if infrequent, side effect of GLP-1 medicines in a January 2026 Drug Safety Update. Signs of a serious allergic reaction (swelling, difficulty breathing, rapid heartbeat) also require emergency care. If you are unsure about a symptom, contact your prescriber or call 111. Do not wait for your next scheduled review.

Fatigue, mild headache, and dizziness also appear in this early window for some people, often linked to reduced calorie intake rather than the medicine itself. Protein intake, hydration, and not skipping meals entirely all help. The Mounjaro weight loss expectations page covers how to support early progress through diet alongside treatment.

What happens next: the step from week 3 into week 4 and beyond

Most titration schedules involve staying on 2.5 mg for the first four weeks before a prescriber considers moving to 5 mg. Week 3 sits inside that window, so the clinical focus right now is on tolerating the current dose well rather than increasing it. That is intentional. Moving too quickly through doses increases the likelihood of side effects without necessarily improving outcomes.

The shift to week 4 (and the question of what changes then) is worth understanding in advance. The Mounjaro week 4 guide covers what a dose review typically involves and what the prescriber looks for before recommending an increase. At nume, every dose progression requires clinical evidence and a fresh review; no dose change is automatic.

If by the end of week 3 you have noticed very little in the way of appetite change or any other effect, that is not necessarily cause for concern at 2.5 mg. Some people respond more noticeably at higher doses. Others find the early response subtle and the change more apparent when they look back over four to six weeks rather than day by day. The page on no weight loss in week 3 on Mounjaro addresses this specific concern in full, including when it is and is not worth raising with your prescriber.

For anyone considering starting treatment or thinking about switching provider, the Mounjaro overview explains the full picture, UK licensing, eligibility criteria, and how private prescribing works through a GPhC-registered pharmacy. Mounjaro is a prescription-only medicine; accessing it safely means a clinical assessment first, not a purchase.